anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, homeopathy, pharmacy. SUBSTANCE: invention relates to the development of homeopathic cholagogic agent. Invention proposes the composition containing Carduus marianus C3, Citrulus colocynthis C6, Lycopodium clavatum C12, Chelidonium majus C6 taken in equal ratios. The composition represents the homeopathic medicinal agent made as sugar granules. The dose of this agent in patients results to disappearance severity and pain in right hypochondrium and epigastric region and eructation. EFFECT: valuable medicinal properties. 2 cl, 1 ex
The invention discloses breast enlargement and beauty cream which comprises the following ingredients in percentage by weight: 15-20 percent of an emollient, 3-5 percent of an emulsifier, 5-20 percent of a moisturizer, 0.5-1 percent of a nutrient, 40-60 percent of functional active components, 0.2-0.5 percent of preservative and antioxidants, and 40-50 percent of a filler. The emollient comprises stearic acid, cetearyl alcohol, glyceryl stearate and shea butter. The emulsifier comprises PPG-1trideceth-6, PEG-100glyceryl stearate and pentaerythrityl tetraisostearate. The moisturizer comprises 6 percent butanediol, glycerin and trimethyl glycine. The nutrient comprises sodium hyaluronate HA, beta-sitosterol, tocopherol and oil soluble azone. The functional active components comprise the following ingredients in mass percent: 5-10 percent of semen sinapis extracting solution, 5-10 of percent soy isoflavones extracting solution, 8-15 percent of leonurus artemisia extracting solution, 8-15 percent of kudzuvine root extracting solution and 10-15 percent of humulus lupulus extracting solution. The filler is water. The breast enlargement and beauty cream has the functions of breast enlargement and health care, and can maintain the health and shape of breasts in an all-dimensional, safe and effective manner.
Subjects will receive standard of care treatments from their physical therapist. Evaluations will be completed at baseline, week 4, and week 8 for all subject groups. Evaluations will consist of a strength assessment, standard clinical questionnaires about back health, a Sorenson's Back Endurance Test, and ultrasound images of back musculature. Longitudinal follow-ups will be completed quarterly for one year after the initial evaluation. These follow-ups will be performed remotely via phone and/or email and incorporate clinical questionnaires.
Patients with CDH1 or CTNNA1 germline pathogenic variant. No history of diffuse gastric cancer.
A microparticle has a core comprising an aqueous phase including (i) a bioactive material comprising an extracellular vesicle (e.g., exosome) or a material derived from a cell and (ii) an optional hydrophilic stabilizing agent. An amphiphilic layer is disposed around the core and has a biodegradable amphiphilic block copolymer comprising hydrophilic and hydrophobic domains capable of self-assembly to define a core-shell structure. An aqueous shell layer may be temporarily disposed over the amphiphilic layer. The microparticle has a diameter of ≥ about 1 ≤ about 100 micrometers and releases the bioactive material for ≥ about 6 weeks when exposed to an aqueous medium. A tissue regeneration system can be implanted in a subject and may include a biocompatible tissue reconstruction material with the controlled release microparticles distributed therein. Methods of making controlled release microparticles are also provided, which form water-in-oil-in-water emulsions that are solidified.
Patients receive gemcitabine hydrochloride IV qw 3/4 wk or gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation IV qw 3/4 wk in the absence of disease progression or recurrence per standard of care. Tissue and blood samples are collected for genetic analysis via sequencing.
FIELD: chemical industry. SUBSTANCE: method comprises reacting 3-(2- aminoethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido [1,2-a] pyrimidin-4-one (II) with isoxazole derivative of formula III   wherein Y and Z are removable groups such as halogen or alkyl-or arylsulfonyloxy group in the presence of suitable solvent and base. The method makes it possible to simplify process for preparation of compound (I) due to using more readily available reagents. The present invention also describes compounds II and III. EFFECT: more efficient preparation method. 8 cl, 8 ex
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, in particular to ophthalmology and deals with treatment of intraocular infections. For this purpose on eye cornea placed is soft contact lens, made from polymer methacrylate and saturated with 0.5% solution of levofloxacyne in doze of 0.9 g. After two hours intravenous infusion of levofloxacyne solution in the same dose and 16 mg of dexamethazone is performed. An hour later contact lens is removed from eye cornea and second similar lens, also saturated with 0.5% levofloxacyne solution in dose 0.9 g, is placed on cornea. After 5 hours lens is removed. ^ EFFECT: method ensures efficient treatment in case of purulent diseases of cornea, infection inflammation of iris and ciliary body due to long, even supply of antibiotic in anterior eye chamber. ^ 1 ex
Inhaled aeroallergens can directly activate airway epithelial cells (AECs). Exposure to cockroach allergens is a strong risk factor for asthma. Cockroach allergens mediate some of their effects through their serine protease activity; protease activity is also a major contributor to allergenicity. The Th2 cytokine interleukin-13 (IL-13) induces upregulation of the eosinophil chemotactic factor CCL26. CCL26 induces eosinophil migration in allergic inflammation. In this work, we studied the effect of cockroach proteases on IL-13-induced effects. Immersed cultures of the human bronchial epithelial cell line BEAS-2B and air-liquid interface (ALI) cultures of primary normal human bronchial epithelial (NHBE) cells were stimulated with IL-13, Blattella Germanica cockroach extract (CE), or both. IL-13-induced genes were analyzed with qRT-PCR. IL-13 induced upregulation of CCL26, periostin, and IL-13Rα2 in bronchial epithelial cells which were decreased by CE. CE was heat-inactivated (HICE) or pre-incubated with protease inhibitors. HICE and CE preincubated with serine protease inhibitors did not prevent IL-13-induced CCL26 upregulation. CE-degraded IL-13 and specific cleavage sites were identified. CE also decreased IL-4-induced CCL26 upregulation and degraded IL-4. Other serine proteases such as bovine trypsin and house dust mite (HDM) serine proteases did not have the same effects on IL-13-induced CCL26. We conclude that CE serine proteases antagonize IL-13-induced effects in AECs, and this CE effect is mediated primarily through proteolytic cleavage of IL-13. IL-13 cleavage by cockroach serine proteases may modulate CCL26-mediated effects in allergic airway inflammation by interfering directly with the pro-inflammatory effects of IL-13 in vivo.
Patients receive BEAM comprising carmustine IV over 4 hours on day -6; cytarabine IV over 2 hours BID on days -5 to -2; etoposide IV over 1 hour BID or QD on days -5 to -2; and melphalan IV on day -1. Patients then undergo autologous hematopoietic stem cell transplant on day 0.
<P>PROBLEM TO BE SOLVED: To allow the inhibition of monocyte attractant activity by mutating a region of MCP-1.  <P>SOLUTION: Successful inhibition of the monocyte attractant activity has been found where the MCP-1 is modified in one or more of the followings: (a) the 28-tyrosine is substituted by aspartate, (b) the 24-arginine is substituted by phenylalanine, (c) the 3-aspartate is substituted by alanine, and/or (d) the 2-8 amino acid sequence is deleted. The claimed MCP-1 derivatives can be administered to a patient in need of inhibiting MCP-1 monocyte attractant activity. For example, the derivatives can be used to prevent restenosis, such as that which is common to patients undergoing coronary artery angioplasty. The invention further relates to compositions and methods of inhibiting monocyte attractant activity of MCP-1 employing the derivatives described.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Metabolic dysfunction-associated steatotic liver disease (MASLD) has garnered considerable attention globally. Changing lifestyles, over-nutrition, and physical inactivity have promoted its development. MASLD is typically accompanied by obesity and is strongly linked to metabolic syndromes. Given that MASLD prevalence is on the rise, there is an urgent need to elucidate its pathogenesis. Hepatic lipid accumulation generally triggers lipotoxicity and induces MASLD or progress to metabolic dysfunction-associated steatohepatitis (MASH) by mediating endoplasmic reticulum stress, oxidative stress, organelle dysfunction, and ferroptosis. Recently, significant attention has been directed towards exploring the role of gut microbial dysbiosis in the development of MASLD, offering a novel therapeutic target for MASLD. Considering that there are no recognized pharmacological therapies due to the diversity of mechanisms involved in MASLD and the difficulty associated with undertaking clinical trials, potential targets in MASLD remain elusive. Thus, this article aimed to summarize and evaluate the prominent roles of lipotoxicity, ferroptosis, and gut microbes in the development of MASLD and the mechanisms underlying their effects. Furthermore, existing advances and challenges in the treatment of MASLD were outlined.
Using the AHA's CPR Anytime kit, we will work with family members of patients at high risk for a CA to learn lifesaving CPR skills. We will modify the AHA CPR video using the new AHA recommendations for bystanders which suggests doing chest compression only CPR. Using the original AHA video and our modified chest compression only video, we will randomize family members of patients at high risk for CA to one of these groups. Our research assistants will also be blinded to which video these subjects will be watching. After watching the video, we will have the subjects perform CPR on a mannequin using a CPR recording device that records chest compression rate and depth. We will follow up with the family members at 3 months, 6 months and 12 months to see if they retained their CPR knowledge and skills and to see if they had been in a situation where their CPR skills were needed and assess whether they performed their skills or not. We will also measure the number of people with whom the subjects shared their CPR Anytime kits-a quantity known as the multiplier effect to determine if they had shared the CPR Anytime kit with their family and friends, thereby increasing the possible number of lay persons trained in CPR and in turn able to perform bystander CPR if needed.
The present invention relates to biocompatible protein-based particles and their methods of preparation and use. More specifically the present invention relates protein-based particles including protein matrix, spread matrix and/or biocoacervate materials derived from one or more biocompatible purified proteins combined with one or more biocompatible solvents that are used to replace or repair tissue and/or bone in treatments for spinal disc(s), joint(s) (e.g. knee, hip, finger, ankle, elbow, shoulder . . . ) and organ(s) (e.g. bladder, lips, vagina, penis, urethra . . . ). In various embodiments of the present invention the protein-based particles may also include one or more pharmacologically active agents and/or one or more additives.
The invention relates to medicinal liquor which is prepared from traditional Chinese medicines and has the effects of relieving pain and relieving itching, and the preparation method thereof, and belongs to the traditional Chinese medicines. The medicinal liquid is prepared from the following traditional Chinese medicines in the equal amount: rhizoma coptidis, rheum officinale, licorice root, dried tangerine and drinkable distillate spirits. The preparation method comprises the following steps: selecting the traditional Chinese medicines in the equal amount, cleaning, airing, breaking into pieces and soaking in the drinkable distillate spirits with the alcohol content being between 30 DEG and 75 DEG for 8 to 15 days, wherein the proportion of the traditional Chinese medicine to the drinkable distillate spirits is 1:(8 to 10). The medicinal liquor ensures the compatibility of rhizoma coptidis, rheum officinale and dried tangerine and adopts licorice root to harmonize, therefore, the medicinal liquor has the effects of reducing fever, eliminating dampness, promoting urination, detoxifying, purging heat, relaxing bowels, neutralizing poison, treating boils, absorbing clots, restoringmenstrual flow, clearing heat, removing dampness, regulating vital energy flow, strengthening spleen, eliminating dampness, dissipating phlegm, detoxifying, removing phlegm, relieving pain and relieving convulsion. The medicinal liquor has the significant curative effects on the skin diseases with the cardinal symptoms being rheumatalgia caused by rheumatism bone and muscle pain and apoplexy and itching of skin. The medicinal liquor has the advantages of easily available medicinal material, simple formula, low cost, convenient administration and immediate effect, and suits wide application.
BACKGROUND: Vascular plug-assisted retrograde transvenous obliteration (PARTO) obliterates the gastric varices and portosystemic shunt, thus resulting in a lower rebleeding rate than endoscopic glue/sclerotherapy.
AIMS: To evaluate the safety and efficacy of PARTO as salvage therapy in liver cirrhosis with gastric variceal bleed (GVB) after failed endotherapy. We assessed the clinical success rate and changes in liver function at 6- months.
MATERIALS AND METHODS: Patients who underwent salvage PARTO after failed endotherapy for GVB (between December 2021 and November 2022) were searched and analyzed from the hospital database. Clinical success rate and rebleed rate were obtained at six months. Child-Pugh score (CTP) and Model for end-stage liver disease (MELD) score were calculated and compared between baseline and 6-month follow-up.
RESULTS: Fourteen patients (n = 14, Child-Pugh class A/B) underwent salvage PARTO. Nine had GOV-2, and five had IGV-1 varices. The mean shunt diameter was 11.6 ± 1.6 mm. The clinical success rate of PARTO was 100% (no recurrent gastric variceal hemorrhage within six months). No significant deterioration in CTP (6.79 ± 0.98 vs. 6.21 ± 1.52; p = 0.12) and MELD scores (11.5 ± 4.05 vs. 10.21 ± 3.19; p = 0.36) was noted at 6 months. All patients were alive at 6 months. One patient (n = 1, 7.1%) bled from esophageal varices after three days of PARTO and was managed with variceal banding. 21.4% (3/14) patients had progression of esophageal varices at 6 months requiring prophylactic band ligation. Three patients (21.4%) had new onset or worsening ascites and responded to low-dose diuretics therapy.
CONCLUSIONS: PARTO is a safe and effective procedure for bleeding gastric varices without any deterioration in liver function even after six months. Patient selection is critical to prevent complications. Further prospective studies with larger sample size are required to validate our findings.
Sclerosing oleogranuloma of the penis is a rare benign condition characterized by the formation of rough and dense infiltrates in the male genital area following injection of foreign materials under the skin for the purpose of augmentation. It predominantly affects males of reproductive age. Diagnosis is based on patients history, examination and histological findings. Treatment involves excision of the granuloma and affected tissues with surgical margins followed by reconstruction of the penis and scrotum. A clinical case of the treatment of giant oleogranuloma of the penis and scrotum in a 21-year-old man clinically manifested by painful multiple lesions under the skin with ulceration along the coronal sulcus, pain, deterioration of the quality of life and cosmetic issues is presented in the article. For surgical treatment, the one-stage Sapozhkov-Reich procedure was performed for the first time at the urology department of the Republican Hospital named after V.A. Baranov, Petrozavodsk. Keywords: sclerosing lipogranuloma of the penis, sclerosing lipogranuloma of the scrotum, penis augmentation, injections into the penis, vaselinome, one-stage Sapozhkov-Reich procedure Author contributions. Simanov R.N. - idea, concept and design of writing the article, literature review, collection and processing of information and materials, description of a clinical case, analysis of patient carts, surgical treatment, writing text and preparing illustrative materials for publication; 60% of the work. Malyshev E.V. - surgical treatment, collection and processing of information, description of a clinical case; 20% of the work. Smirnova D.V. - collection and processing of clinical data, assistance in writing an article, preparation of a description of histological examination and micropreparations, creation of microphotographs, preparation of illustrative materials for publication; 20% of the work.
INTRODUCTION: Gaps exist in the understanding of the etiology of poor sleep quality after lung transplantation. Research Question: What factors are associated with poor sleep quality in lung transplant recipients?
DESIGN: A quantitative, single-site, cross-sectional study used an anonymous survey based on 3 scales. The Pittsburgh Sleep Quality Index scale with scores dichotomized to poor versus good sleepers based on the cutoff score > 8. The Hospital Anxiety and Depression Scale evaluated symptoms of anxiety and depression, and the Short Form-12 measured health-related quality of life using the mental and physical component scores. Additional self-reported data included demographic and transplant-related variables.
RESULTS: The response rate was 38.4% (61/158), and 52.5% of the sample (32/61) evidenced a Pittsburgh Sleep Quality Index score > 8, suggestive of poor sleep quality. Bivariate analyses demonstrated that poor sleep was significantly related to symptoms of depression (P < .01), anxiety (P < .01), stressors of hospitalization (P < .05), and treatment of acute rejection (P < .05). Multivariate analysis demonstrated that anxiety was significantly associated with poor sleep (odds ratio = 1.34, P < .05).
CONCLUSION: Poor subjective sleep quality remains prevalent in lung transplant recipients. Individuals with anxiety symptoms were at a greater risk for poor sleep. Guidance for strategies to improve sleep quality requires further in-depth exploration before implementation of interventions.
Study patients are notified of their "diagnostic" test result within 72 hours. Those identified as potentially pre-diabetic or diabetic and randomized to the enhanced group, receive a tailored message about their modifiable risks and are advised to see their physician regarding their test results. They are given a letter to take to their physician and receive a call at month two and then again at month four if necessary to inquire if they have followed-up with their physician and encouragement to do so, if they have not, prior to their six month follow-up study visit.
Ultramarathons are a unique model to study the effects of systemic fatigue in athletes. This investigation applied the spring-mass template to study runners before and 2 days after a road ultramarathon to characterize the effects of fatigue on systemic gait patterns. Overground kinetics were captured 7 days before and 2 days after the event in 14 runners. Traditional kinetic and spring-mass parameters were calculated, along with nonlinear regression-derived parameters and spring-mass model fit metrics. After the ultramarathon, vertical force magnitudes and loading rates were unchanged, but impact peaks increased (1.88 ± 0.08-1.95 ± 0.10 bodyweight). Ground contact times were modestly shorter (-3 ± 1 ms), resulting in increased leg stiffness (10.0 ± 0.5-10.3 ± 0.5 kN/m) with equivocal vertical stiffnesses. The deviation from the modeled spring-mass kinetics also increased (171.3 ± 15.0-181.4 ± 16.5 N). Overall, the systemic mechanical behaviors of the runners persisted despite the fatigue and stress induced by a road ultramarathon. These findings support previous observations that runners maintain gross mechanical behavior when fatigued with small compensatory changes in spatiotemporal and traditional spring-mass characteristics. However, these findings also suggest that the variability within that gross behavior may increase after stress, suggesting new opportunities for quantifying those deviations.
BACKGROUND: Postburn scarring alopecia on hair-bearing aesthetic subunits causes cosmetic disfiguring and psychological problems. Follicular unit extraction (FUE) hair transplantation is an effective technique for camouflaging postburn scarring alopecia. However, poorly vascularized and fibrotic scar tissue limits the viability of grafts. The mechanical and vascular characteristics of scar tissue can be improved by nanofat grafting. This study aimed to present the results of postburn scarring alopecia treatment using nanofat-assisted FUE hair transplantation.
METHODS: Eighteen patients who had postburn scarring alopecia in and around the beard were enrolled. Patients underwent single-session nanofat grafting and FUE hair transplantation at 6-month intervals. Twelve months after hair transplantation, the survival rate of transplanted follicular graft, scar improvement, and patient satisfaction were assessed by counting each transplanted follicle individually, using the Patient and Observer Scar Assessment Scale, and using a 5-point Likert satisfaction scale, respectively.
RESULTS: Nanofat grafting and hair transplantation were successfully performed without complication. All scars significantly improved in mature characteristics ( P < 0.00001 for patients; P < 0.00001 for observers). The survival and density rates of transplanted follicular units ranged from 77.4% to 87.9% (mean, 83.2% ± 2.5%) and 10.7% to 19.6% (mean, 15.2% ± 2.46%), respectively. All patients reported significantly satisfying cosmetic results ( P < 0.00001).
CONCLUSIONS: Scarring alopecia is an inevitable and challenging late complication of deep burned hair-bearing units. Combining nanofat injection and FUE hair transplantation is among the most innovative and effective treatments for postburn scarring alopecia.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
Background: Accurate identification of fetal growth restriction in fetal autopsy is critical for assessing causes of death. We examined the impact of using a chart derived from ultrasound measurements of healthy fetuses (World Health Organization fetal growth chart) versus a chart commonly used by pathologists (Archie et al.) derived from fetal autopsy-based populations in diagnosing small-for-gestational-age (SGA) birth in perinatal deaths. Study Design: We examined perinatal deaths that underwent autopsy at BC Women's Hospital, 2015-2021. Weight centiles were assigned using the ultrasound-based fetal growth chart for birthweight and autopsy-based growth chart for autopsy weight. Results: Among 352 fetuses, 30% were SGA based on the ultrasound-based fetal growth chart versus 17% using the autopsy-based growth chart (p < 0.001). Weight centiles were lower when using the ultrasound-based versus autopsy-based growth chart (median difference of 9 centiles [IQR 2, 20]). Conclusions: Autopsy-based growth charts may under-classify SGA status compared to ultrasound-based fetal growth charts.
FIELD: organic chemistry, medicine, pharmacy. SUBSTANCE: invention describes the novel compounds of the general formula (I)   where values R 1 -R 5 ,R 14 , Q, n are given in p. 1 of the invention claim. Compounds show the selective activity with respect to specific receptors of retinoic acid. They can be used for treatment of patients with different pathological states. Invention describes also pharmaceutical composition based on compounds of the formula (I) and the method of SUPPRESSION of pathological states and the method of modulation of processes (variants). EFFECT: valuable properties of new compounds. 26 cl, 12 dwg, 51 ex